Oregonian

People’s Pharmacy: Study finds limited stroke protection from bempedoic acid

Q. I read the breathless announcements about bempedoic acid and how effective it is at lowering cholesterol. This is all well and good, but what we care about is how effective it is at preventing ...

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years –– A Secondary Analysis of CLEAR Outcomes Reports on Patient ...
C&EN

Bempedoic acid

Bempedoic acid is a hydroxyalkane diacid and the active ingredient in hypercholesteremia medication. Under the name ESP 55016, it was first described in 2004 by Michael E. Pape and co-workers at ...

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients ...
Nasdaq

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese ...